{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:33:53Z","timestamp":1791232433371,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.leukres.2012.12.017","type":"journal-article","created":{"date-parts":[[2013,1,19]],"date-time":"2013-01-19T08:45:20Z","timestamp":1358585120000},"page":"427-433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["5\u2032-OH-5-nitro-Indirubin oxime (AGM130), an Indirubin derivative, induces apoptosis of Imatinib-resistant chronic myeloid leukemia cells"],"prefix":"10.1016","volume":"37","author":[{"given":"Woo-Seok","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do-Hyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Il","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Chul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi-Ryoung","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Gyoo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2012.12.017_bib0005","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7326\/0003-4819-131-3-199908030-00008","article-title":"Chronic myelogenous leukemia: biology and therapy","volume":"131","author":"Faderl","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.leukres.2012.12.017_bib0010","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2012.12.017_bib0015","doi-asserted-by":"crossref","first-page":"819","DOI":"10.7326\/0003-4819-138-10-200305200-00010","article-title":"Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics","volume":"138","author":"Kurzrock","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.leukres.2012.12.017_bib0020","first-page":"751","article-title":"The molecular biology of chronic myeloid leukaemia","volume":"10","author":"Melo","year":"1996","journal-title":"Leukemia: Off J Leuk Soc Am Leuk Res Fund UK"},{"key":"10.1016\/j.leukres.2012.12.017_bib0025","first-page":"3116","article-title":"Detection of c-Abl tyrosine kinase activity in vitro permits direct comparison of normal and altered Abl gene products","volume":"5","author":"Konopka","year":"1985","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.leukres.2012.12.017_bib0030","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc2126","article-title":"Second generation inhibitors of BCR\u2013ABL for the treatment of Imatinib-resistant chronic myeloid leukaemia","volume":"7","author":"Weisberg","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.leukres.2012.12.017_bib0035","first-page":"511","article-title":"The Ras-Raf-MEK-ERK pathway in the treatment of cancer","volume":"25","author":"Hilger","year":"2002","journal-title":"Onkologie"},{"key":"10.1016\/j.leukres.2012.12.017_bib0040","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0092-8674(04)00003-0","article-title":"Rho and Rac take center stage","volume":"116","author":"Burridge","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2012.12.017_bib0045","first-page":"541","article-title":"Regulation of ERalpha-mediated transcription of Bcl-2 by PI3K\u2013Akt crosstalk: implications for breast cancer cell survival","volume":"37","author":"Bratton","year":"2010","journal-title":"Int J Oncol"},{"key":"10.1016\/j.leukres.2012.12.017_bib0050","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.tibs.2007.12.002","article-title":"Mining for JAK-STAT mutations in cancer","volume":"33","author":"Constantinescu","year":"2008","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.leukres.2012.12.017_bib0055","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ceb.2009.01.014","article-title":"The interplay of structural information and functional studies in kinase drug design: insights from BCR\u2013ABL","volume":"21","author":"Eck","year":"2009","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.leukres.2012.12.017_bib0060","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/asheducation-2009.1.461","article-title":"Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance","author":"Bixby","year":"2009","journal-title":"Hematology: Am Soc Hematol Educ Program"},{"key":"10.1016\/j.leukres.2012.12.017_bib0065","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1038\/sj.onc.1201400","article-title":"The Bcr\u2013Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells","volume":"15","author":"Cortez","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2012.12.017_bib0070","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S1535-6108(02)00074-0","article-title":"Critical role for Gab2 in transformation by BCR\/ABL","volume":"1","author":"Sattler","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2012.12.017_bib0075","doi-asserted-by":"crossref","first-page":"e6124","DOI":"10.1371\/journal.pone.0006124","article-title":"ERK2, but not ERK1, mediates acquired and \u201cde novo\u201d resistance to Imatinib mesylate: implication for CML therapy","volume":"4","author":"Aceves-Luquero","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.leukres.2012.12.017_bib0080","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr\u2013Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O\u2019Hare","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.12.017_bib0085","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR\u2013ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.leukres.2012.12.017_bib0090","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1182\/blood.V95.11.3498","article-title":"Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR\/ABL-transformed hematopoietic cell lines","volume":"95","author":"Weisberg","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.12.017_bib0095","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature09883","article-title":"BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR\u2013ABL1 kinase inhibition","volume":"473","author":"Duy","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2012.12.017_bib0100","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1084\/jem.20112087","article-title":"Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks","volume":"208","author":"Pellicano","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.leukres.2012.12.017_bib0105","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/9035","article-title":"Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases","volume":"1","author":"Hoessel","year":"1999","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.leukres.2012.12.017_bib0110","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00432-004-0579-2","article-title":"Molecular mechanisms of Indirubin and its derivatives: novel anticancer molecules with their origin in traditional Chinese phytomedicine","volume":"130","author":"Eisenbrand","year":"2004","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.leukres.2012.12.017_bib0115","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1042\/bj20021535","article-title":"The specificities of protein kinase inhibitors: an update","volume":"371","author":"Bain","year":"2003","journal-title":"Biochem J"},{"key":"10.1016\/j.leukres.2012.12.017_bib0120","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/ijc.2910180405","article-title":"Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia","volume":"18","author":"Klein","year":"1976","journal-title":"Int J Cancer"},{"key":"10.1016\/j.leukres.2012.12.017_bib0125","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0145-2126(79)90033-X","article-title":"Properties and usefulness of the original K-562 human myelogenous leukemia cell line","volume":"3","author":"Lozzio","year":"1979","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2012.12.017_bib0130","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1124\/jpet.107.124461","article-title":"Bcr\u2013Abl-independent Imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors","volume":"322","author":"Lee","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.leukres.2012.12.017_bib0135","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.leukres.2008.09.024","article-title":"Imatinib resistance in multidrug-resistant K562 human leukemic cells","volume":"33","author":"Assef","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2012.12.017_bib0140","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1242\/dmm.000976","article-title":"Mouse xenograft models vs GEM models for human cancer therapeutics","volume":"1","author":"Richmond","year":"2008","journal-title":"Dis Models Mech"},{"key":"10.1016\/j.leukres.2012.12.017_bib0145","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1242\/jcs.01227","article-title":"Molecular mechanisms of E2F-dependent activation and pRB-mediated repression","volume":"117","author":"Frolov","year":"2004","journal-title":"J Cell Sci"},{"key":"10.1016\/j.leukres.2012.12.017_bib0150","doi-asserted-by":"crossref","first-page":"8313","DOI":"10.1074\/jbc.271.14.8313","article-title":"Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites","volume":"271","author":"Knudsen","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2012.12.017_bib0155","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0092-8674(95)90385-2","article-title":"The retinoblastoma protein and cell cycle control","volume":"81","author":"Weinberg","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2012.12.017_bib0160","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.molonc.2012.02.002","article-title":"Indirubin derivatives induce apoptosis of chronic myelogenous leukemia cells involving inhibition of Stat5 signaling","volume":"6","author":"Nam","year":"2012","journal-title":"Mol Oncol"},{"key":"10.1016\/j.leukres.2012.12.017_bib0165","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/j.leukres.2009.09.001","article-title":"Imatinib achieved complete cytogenetic response in a CML patient received 32-year Indirubin and its derivative treatment","volume":"34","author":"Chen","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2012.12.017_bib0170","first-page":"246","article-title":"Treatment of chronic myelocytic leukemia (CML) by traditional Chinese medicine and Western medicine alternately","volume":"5","author":"Zhang","year":"1985","journal-title":"J Tradit Chin Med"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212612005024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212612005024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:58:03Z","timestamp":1758934683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212612005024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0145212612005024"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2012.12.017","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"5\u2032-OH-5-nitro-Indirubin oxime (AGM130), an Indirubin derivative, induces apoptosis of Imatinib-resistant chronic myeloid leukemia cells","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2012.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}